Talha Badar/X
Jul 13, 2025, 14:35
Talha Badar: Early View of the Phase 1 Study of Blinatumomab Post alloHCT
Talha Badar, Hematology/Oncology Specialist at Mayo Clinic, shared a post on X:
“Early View | Haematologica
Phase 1 study (Blinatumomab post alloHCT for 2 cycles among patients in CR2 (children and young adults) ALL
Most of the G4 toxicities were hematological.
Almost all patients received Blinatumomab pre-alloHCT.”
More posts featuring Blinatumomab.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 13, 2025, 14:35
Jul 13, 2025, 14:35
Jul 13, 2025, 14:32
Jul 13, 2025, 14:29
Jul 13, 2025, 13:57
Jul 13, 2025, 13:54
Jul 13, 2025, 13:50
Jul 13, 2025, 13:47
Jul 13, 2025, 13:40
Jul 13, 2025, 13:34